ATS 2022
TRAVERSE Trial of Dupilumab for Severe Oral Corticosteroid-Dependent Asthma
TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe OCS-dependent asthma were presented at ATS 2022.
Your search for oral corticosteroids returned 9 results
ATS Virtual Program 2020
Low-Severity COPD: Risk for Exacerbation, Hospitalization, and Death
What is the risk of future COPD exacerbations, hospitalizations, and death among patients with COPD who had 1 or 0 exacerbation in the previous 12 months?
News
Tacrolimus May Be an Alternative for First-Line Lupus Nephritis Therapy
In a study, the calcineurin inhibitor tacrolimus proved to be noninferior to intravenous cyclophosphamide.
AAAAI 2022
Azithromycin and Recurrent Wheeze in Children After Severe RSV Bronchiolitis
Research presented at AAAAI assessed the effectiveness of oral azithromycin in reducing recurrent wheeze in young children.
AAAAI 2022
Atopy Status of Patients With Asthma and Exacerbation Rates Post COVID-19
Does the allergic status of patients with asthma affect asthma exacerbation rates and outcomes following COVID-19?
AAAAI 2022
Escalation to Biologics in Asthma: The Role of Suboptimal Treatment Adherence
To what extent are patients with uncontrolled asthma switched to biologics due to poor treatment adherence vs lack of maintenance therapy efficacy?
News
Yescarta Labeling Updated to Include Prophylactic Corticosteroid Use
The updated labeling is based on results from a safety management cohort from the ZUMA-1 study.
News
Cibinqo Approved for Refractory, Moderate to Severe Atopic Dermatitis
The approval was based on data from the phase 3 JADE clinical trial program, which included the JADE MONO-1, JADE MONO-2, and JADE COMPARE trials.
News
Rinvoq Gains FDA Approval for Atopic Dermatitis
The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.
